image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - IN
$ 12.825
0.352 %
$ 10.7 B
Market Cap
17.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one RDY stock under the worst case scenario is HIDDEN Compared to the current market price of 12.8 USD, Dr. Reddy's Laboratories Limited is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one RDY stock under the base case scenario is HIDDEN Compared to the current market price of 12.8 USD, Dr. Reddy's Laboratories Limited is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one RDY stock under the best case scenario is HIDDEN Compared to the current market price of 12.8 USD, Dr. Reddy's Laboratories Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
279 B REVENUE
13.54%
67.7 B OPERATING INCOME
-29.66%
55.7 B NET INCOME
-7.94%
45.4 B OPERATING CASH FLOW
-22.83%
-40.3 B INVESTING CASH FLOW
2.63%
-3.76 B FINANCING CASH FLOW
85.99%
83.6 B REVENUE
4.27%
18.7 B OPERATING INCOME
6.66%
14 B NET INCOME
4.64%
6.62 B OPERATING CASH FLOW
-28.94%
-5.46 B INVESTING CASH FLOW
71.38%
590 M FINANCING CASH FLOW
-96.35%
Balance Sheet Dr. Reddy's Laboratories Limited
image
Current Assets 248 B
Cash & Short-Term Investments 81.5 B
Receivables 80.3 B
Other Current Assets 86.3 B
Non-Current Assets 139 B
Long-Term Investments 5.26 B
PP&E 76.9 B
Other Non-Current Assets 57.3 B
Current Liabilities 96 B
Accounts Payable 21.5 B
Short-Term Debt 14 B
Other Current Liabilities 60.5 B
Non-Current Liabilities 10.9 B
Long-Term Debt 5.99 B
Other Non-Current Liabilities 4.94 B
EFFICIENCY
Earnings Waterfall Dr. Reddy's Laboratories Limited
image
Revenue 279 B
Cost Of Revenue 116 B
Gross Profit 164 B
Operating Expenses 95.9 B
Operating Income 67.7 B
Other Expenses 12 B
Net Income 55.7 B
RATIOS
58.61% GROSS MARGIN
58.61%
24.26% OPERATING MARGIN
24.26%
19.95% NET MARGIN
19.95%
19.85% ROE
19.85%
14.37% ROA
14.37%
17.18% ROIC
17.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Dr. Reddy's Laboratories Limited
image
Net Income 55.7 B
Depreciation & Amortization 14.8 B
Capital Expenditures -27.4 B
Stock-Based Compensation 821 M
Change in Working Capital -20.2 B
Others -15.6 B
Free Cash Flow 18 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Dr. Reddy's Laboratories Limited
image
RDY has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.479 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Dr. Reddy's Laboratories Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15. businesswire.com - 3 weeks ago
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. SHANGHAI , Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. prnewswire.com - 3 weeks ago
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the anticipated Revlimid revenue drop, RDY's new product launches in biosimilars and GLP-1 segments are expected to offset losses, driving future growth. RDY's current P/E ratio of 17.7x is near historical lows; a conservative 23x PE, which is equal to the peer median and slightly lower than the median of the historical range. seekingalpha.com - 1 month ago
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same. zacks.com - 1 month ago
Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli – Chief Executive Officer M V Narasimham – Chief Financial Officer Conference Call Participants Kunal Dhamesha – Macquarie Neha Manpuria – Bank of America Amey Chalke – JM Financial Bino Pathiparampil – Elara Capital Surya Narayan Patra – PhillipCapital Damayanti Kerai – HSBC Tushar Manudhane – Motilal Oswal Financial Services Saion Mukherjee – Nomura Foram Parekh – Bank of Baroda Capital Market Anubhav Agrawal – UBS Vishal Manchanda – Systematix Shashank Krishnakumar – Emkay Global Operator Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. seekingalpha.com - 1 month ago
Dr. Reddy's Q3 & 9MFY25 Financial Results HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY25--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. businesswire.com - 1 month ago
3 Emerging Market Stocks to Buy as 2024 Wraps Up Here, we have picked three emerging market stocks, QFIN, YTRA and RDY, which are expected to show robust growth in 2025 on their growth strategies and fundamentals. zacks.com - 2 months ago
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable. zacks.com - 2 months ago
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma. zacks.com - 3 months ago
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India. businesswire.com - 3 months ago
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market. businesswire.com - 3 months ago
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets. zacks.com - 3 months ago
8. Profile Summary

Dr. Reddy's Laboratories Limited RDY

image
COUNTRY IN
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 10.7 B
Dividend Yield 0.00%
Description Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Contact 8-2-337, Road No. 3, Hyderabad, 500034 https://www.drreddys.com
IPO Date April 11, 2001
Employees 27048
Officers Mr. Krishna K. Venkatesh B.Pharma M.S. Global Head of Quality and Pharmacovigilance & Member of the Management Council Ms. Archana Bhaskar B.Sc., M.B.A. EVice President, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council Mr. Mannam Venkatanarasimham Chief Financial Officer & Member of the Management Council Mr. Deepak Sapra M.B.A. Chief Executive Officer of API & Services & Member of Management Council Mr. Sanjay Sharma B.Tech. Executive Vice President, Global Head of Global Manufacturing & Member of Management Council Mr. Patrick Aghanian B.A., M.B.A. Chief Executive Officer of European Generics & Member of Management Council Mr. Gunupati Venkateswara Prasad B.E. Co-Chairman, MD & Member of Management Council Mr. Kallam Satish Reddy B.Tech., M.S. Chairman of the Board & Member of the Management Council Mr. Venkata Ramana Motupalli M.B.A. Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council Mr. Erez Israeli M.B.A. Chief Executive Officer & Member of the Management Council